glecaprevir and pibrentasvir · Pellet

What changed in the last 90 days

Every detected change for glecaprevir and pibrentasvir, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

Same drug class

Other molecules FDA puts in Hepatitis C Virus NS3/4A Protease Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

• sofosbuvir, velpatasvir, and voxilaprevir· 1 maker
• elbasvir and grazoprevir· 2 makers

Common questions

Is Glecaprevir and pibrentasvir in shortage right now?

No. FDA does not currently list Glecaprevir and pibrentasvir in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.

Who makes Glecaprevir and pibrentasvir?

2 companies have marketed Glecaprevir and pibrentasvir in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.

What does Glecaprevir and pibrentasvir cost?

The typical pharmacy pays about $152.92 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.